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Background/aim: Iron deficiency anemia (IDA) affects hemoglobin A1c (HbA1c) levels. This study aimed to evaluate the effect of
treatment of iron deficiency anemia on hemoglobin A1c in type 2 diabetic patients.
Materials and methods: Ninety type 2 diabetes mellitus (T2DM) patients with IDA were included in a randomized, placebo-controlled,
single-blind clinical trial. The intervention group (n = 45) received 200 mg/day oral iron for 3 months and the control group (n = 45)
received an oral placebo for the same period. Fasting blood sugar, complete blood count, and HbA1c were measured for all subjects at
the beginning and the end of the trial.
Results: The mean age of the treatment and control group was 51.47 ± 1.05 and 52 ± 1.1 years, respectively. The two groups were not
statistically significantly different with regard to diabetes duration (P = 0.436) and age (P = 0.617). Hemoglobin, mean corpuscular
volume, mean corpuscular hemoglobin, serum iron, ferritin, total iron-binding capacity, and HbA1c were significantly improved in the
intervention group in comparison with the control group (P = 0.005).
Conclusion: Iron status should be considered during the interpretation of the HbA1c concentrations in diabetes mellitus. Iron
replacement therapy can decrease HbA1c in anemic patients with IDA and T2DM.
Key words: Type 2 diabetes mellitus, hemoglobin A1c, iron deficiency anemia

1. Introduction
Anemia is a common problem in the world. Approximately
one-third of patients with anemia have iron deficiency.
Previous studies suggested that iron deficiency anemia
(IDA) affects hemoglobin A1c (HbA1c) levels (1).
The most important factor that determines HbA1c
concentration is the blood glucose level. HbA1c is the
standard for monitoring long-term glycemic control
and estimating complications in diabetes mellitus (2,3).
When plasma glucose is consistently raised, nonenzymatic
glycation of hemoglobin is increased. Erythrocytes have
an average lifespan of 120 days; this alteration reflects the
glycemic history over the previous 2–3 months (4).
HbA1c is increased in patients with diabetes (5).
Several studies have shown that some trace elements such
* Correspondence: r.razmandeh1388@gmail.com

as zinc and chromium are involved in the management of
the secretion and function of insulin (6–8).
Iron is an important cation in many metabolic actions,
and it plays a key role in many physiological functions and
especially in the tricarboxylic acid cycle. Rising Fe levels
inhibit the metabolism of glucose and lead to increases
in blood glucose (9). There have been more reports on
the effects of Fe on blood glucose regulation in diabetes
focused on excessive Fe supply than on lower dosages of
Fe (10).
The World Health Organization has defined
anemia as a hemoglobin level of <13 g/dL for men and
postmenopausal women and <12 g/dL for premenopausal
women, mean corpuscular volume (MCV) of <80 fL, and
mean corpuscular hemoglobin (MCH) of <26 pg/cell and
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based on peripheral blood smears (mostly microcytic
hypochromic) (11,12).
HbA1c level is not affected only by blood glucose levels.
It is also altered in some conditions such as hemolytic
anemia, hemoglobinopathies, acute and chronic blood
loss, pregnancy, and uremia (13). Vitamin B , folate, and
12
IDA have also been shown to affect HbA1c levels. Several
studies suggest that IDA affects the levels of HbA1c.
However, reports on the effects of IDA on HbA1c levels
are inconsistent (14–16).
We conducted this study to evaluate the effects of
treatment of IDA on HbA1c in type 2 diabetes mellitus
(T2DM) patients.
2. Materials and methods
2.1. Study population
Ninety diabetic patients (aged 18–65 years) participated
in this single-blind, randomized clinical trial study. All
of the participants had confirmed IDA (Hb of <12 g/dL
in women and Hb of <13 g/dL in men, or ferritin levels
of <15 ng/mL for women and ferritin levels of <9 ng/
mL for men). Patients with a history of erythropoietin
treatment, oral iron treatment, or blood transfusions
within the 1 or 2 past weeks or Hb of >9 mg/dL, hemolytic
anemia, hemoglobinopathies, renal failure, heart failure,
uremia, pregnancy, lactation, or antibiotic consumption of
quinolone or tetracycline were excluded. Further exclusion
criteria were chronic alcohol abuse, chronic liver disease,
an increase of transaminase levels more than 3 times
above the upper limit of normal, portal hypertension with
esophageal varices, known hypersensitivity to ferrous
sulfate, history of acquired iron overload, myelodysplastic
syndrome, known active infection, clinically significant
overt bleeding, active malignancy, surgery with relevant
blood loss (Hb decrease of >2 mg/dL) within 3 months
before screening or planned surgery within the following 3
months, known infection with human immunodeficiency
virus or hepatitis B or C, and significant cardiovascular
disease. All patients were screened to rule out these
conditions.
Subjects were assigned randomly using a 1:1
randomization ratio to the intervention and placebo
groups. All patients in the intervention group were treated
with oral ferrous sulfate at 200 mg/day for 3 months and
patients in the control group were treated with an oral
placebo (dried breadcrumbs) at 200 mg/day for 3 months.
2.2. Blood measurements
All of the laboratory investigations were performed before
treatment with the iron or placebo and 3 months after
that. The blood specimens were drawn after overnight
fasting. A Sysmex automated hematology analyzer (Japan)
was used for the whole blood counts (hemoglobin (Hb),
haematocrit (Hct), MCV, and MCH). Serum ferritin
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levels were measured using a Hyperion ELISA reader
(Germany), while fasting blood sugar (FBS), total ironbinding capacity (TIBC), and serum iron (SI) were
measured using the BioLife 24i Premium (Boeki Medical
System, Japan). HbA1c levels were determined by highperformance liquid chromatography with a TOSOH-G8
(Japan). Peripheral blood smears were examined for all
patients.
2.3. Statistics
Data are expressed as mean ± SD for continuous variables
and frequency and percent for categorical variables.
Independent t-tests and chi-square tests were used to
compare baseline characteristics. We used repeated
measure ANOVA to compare changes of responses
between the study groups. P < 0.05 was considered
significant. Statistical analysis was performed using SPSS
21 for Windows (IBM Corp., Armonk, NY, USA).
2.4. Ethics
This study was approved by the Ethics Committee of Tehran
University of Medical Sciences, and written consent was
obtained from all of the patients after describing the study
in detail.
3. Result
A total of 45 people were assigned to each group
(intervention and control); mean age was 51.47 ± 1.05
years in the intervention group and 52 ± 1.1 years in
the control group. The two groups were not statistically
significant with regards to diabetes duration (P = 0.436)
or age (P = 0.617).
Thirty percent of participants were male and 70%
were female; the sex ratio was not statistically significant
between the two groups (P = 0.490).
Baseline characteristics of subjects are shown in Table
1. Descriptive statistics of all the parameters that were
tested for both groups are reported in Table 2.
At the start of the study, the two groups were similar
in all indices (P > 0.05) except in red blood cell (RBC)
count, which was significantly greater in the intervention
group than the control group (4.70 ± 0.55 vs 4.32 ± 0.42
with P < 0.001). After treatment there were no significant
differences between the MCV, TIBC, FBS, and HbA1c
values of the two groups (P > 0.05 for mean comparison
of the two groups). In repeated measure ANOVA, time as
a within-subject effect was significant for all indices, and
the change of index between two time points was not the
same among the two groups (P < 0.001, based on time
× group interaction) for all indices with P = 0.005 for
HbA1c, but for RBC count and FBS the changes during
the study period were not statistically significant. As is
obvious from the Figure, the mean reduction of HbA1c
from the beginning to the end of the study was greater
among intervention group than the controls (Table 2).
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Table 1. Baseline characteristics of patients.
Control group (n = 45)

Intervention group (n = 45)

Male

15 (33.3%)

12 (26.7%)

Female

30 (66.7%)

33 (73.3%)

Age

51.47 ± 7.07

52 ± 7.35

0.617

Diabetes duration

10.77 ± 5.69

9.71 ± 5.28

0.436

Sex

P-value
0.490

Table 2. Comparison of anemia indices and glycemic control between intervention and control groups.
Variable

RBC
Count

Hb

MCV

MCH

MCHC

Serum
Iron

Ferritin

TIBC

FBS

Hb A1C

Test
point

Group
Intervention (mean ± SD)

Control (mean ± SD)

P*

Factor

F (P)

Pre

4.70 ± 0.55

4.32 ± 0.42

<0.001

Group

19.24 (<0.001)

Post

4.86 ± 0.41

4.41 ± 0.52

<0.001

Time

13.11 (<0.001)

Time × group

1.11 (0.269)

Pre

11.52 ± 0.86

11.3 ± 0.73

0.287

Group

31.04 (<0.001)

Post

13.71 ± 1.37

11.6 ± 1.24

<0.001

Time

0.014 (<0.001)

Time × group

88.79 (<0.001)

Pre

79.94 ± 6.04

82.08 ± 6.7

0.115

Group

0.041 (0.84)

Post

84.62 ± 4.37

82.99 ± 7.34

0.203

Time

47.75 (<0.001)

Time × group

21.69 (<0.001)

Pre

26.98 ± 3.27

27.65 ± 3.02

0.316

Group

0.69 (0.405)

Post

28.66 ± 2.66

26.98 ± 3.23

0.009

Time

4.74 (0.032)

Time × group

25.70 (<0.001)

Pre

31.84 ± 1.9

31.81 ± 1.73

0.942

Group

4.14 (0.045)

Post

33.38 ± 1.41

32.04 ± 1.98

<0.001

Time

29.05 (<0.001)

Time × group

15.76 (<0.001)

Pre

45.46 ± 29.77

47.35 ± 36.74

0.789

Group

2.76 (0.100)

Post

73.26 ± 34.27

48.56 ± 34.28

0.001

Time

55.61 (<0.001)

Time × group

46.69 (<0.001)

Pre

32.33 ± 39.23

39.37 ± 42.46

0.417

Group

0.82 (0.367)

Post

64.10 ± 56.82

40.56 ± 38.87

0.024

Time

38.27 (<0.001)

Time × group

32.89 (<0.001)

Pre

227.59 ± 116.27

238.37 ± 108.01

0.650

Group

0.300 (0.583)

Post

280.47 ± 85.30

245.94 ± 111.79

0.103

Time

25.56 (<0.001)

Time × group

14.19 (<0.001)

Pre

146.95 ± 42.69

152.62 ± 38.68

0.511

Group

1.63 (0.204)

Post

131.76 ± 41.75

145.60 ± 33.35

0.086

Time

11.88 (0.001)

Time × group

1.61 (0.208)

Pre

7.59 ± 1.16

7.40 ± 1.01

0.419

Group

0.18 (0.676)

Post

6.80 ± 0.85

7.14 ± 0.95

0.740

Time

32.39 (<0.001)

Time × group

8.44 (0.005)

*P-value for independent t-test.
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Figure. Mean change of HbA1c in intervention and control groups.

4. Discussion
The first study to investigate the effects of IDA on HbA1c
levels was by Horton and Huisman (15), who demonstrated
the mean HbA1c concentration for four patients with IDA
as 4.9% compared with a mean HbA1c concentration of
5.3% among 14 healthy people.
Several researchers suggested a potential role of Fe
in the pathogenesis of T2DM, obesity, and metabolic
syndrome. Fe is capable of generating reactive oxygen
species and is elevated in oxidative stress (17,18).
In animal models, its excess might result in pancreatic
oxidative stress and elevated insulin secretary (19). In
the presence of hyperglycemia, Fe may contribute to the
development and progression of oxidative injury and may
also negatively impact glucose control. However, iron
indices are strongly correlated with Hb, which represents
an important risk factor for morbidity and mortality in
patients with diabetes.
IDA is one the most common anemias among the
nutritional anemias in Iran. Brooks et al. (20), GramHansen et al. (21), and Coban et al. (22) previously
demonstrated the effects of treatment of IDA in patients
with T2DM and found a significant reduction in HbA1c
levels after iron therapy.
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Anemia is caused by decreased or faulty RBC
production, and the consequently increased mean age of
circulating RBCs leads to elevated HbA1c levels (23).
Comparing several studies, the different changes in
HbA1c levels were due to different laboratory methods,
control of blood glucose, pregnancy, metabolic status and
chronic kidney disease, or very little positive correlation
with age (14,24–26).
Hashimoto et al. found that HbA1c levels were
significantly raised in the third trimester, but serum
glycated albumin did not change; HbA1c was not correlated
with serum ferritin, and it was suggested that HbA1c
was affected by iron stores. Furthermore, iron therapy
was associated with decreases in HbA1c, independent of
changes in blood glucose (27,28).
Arredondo et al. explained a similar relation among
iron indices in diabetic patients or patients with metabolic
syndrome. However, increasing iron store is not necessarily
a usual factor for diabetes. Their results supported the
idea that patients with increased iron stores have a higher
predisposition to develop noninsulin-dependent diabetes
(29).
Rafat et al. showed that Hb concentrations were
positively correlated with HbA1c concentrations, whereby
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HbA1c concentrations tended to be increased in the
presence of iron deficiency. The positive correlation
between HbA1c concentrations and Hb may have offset the
small inverse association between HbA1c concentrations
and iron status. A potential caveat lies in the inclusion of
serum ferritin as a component in our diagnosis of iron
deficiency, because ferritin has been recognized as an
inflammatory marker associated with insulin resistance
(24). In contrast, Saudek et al. explained measurements of
HbA1c to be invalid in the presence of anemia (30).
IDA not only increases HbA1c levels in nondiabetic
patients; it can also show the glycemic status in patients
with T2DM. Our results demonstrate that there is a relation
between iron therapy and HbA1c in patients with T2DM.
This is in agreement with the studies of Brooks et al. and
Davis et al. (20,31). They defined a relationship between
IDA and HbA1c levels and tried to explain the alteration
in HbA1c levels in IDA on the basis of both alterations in
the form of hemoglobin and levels of HbA1c in old and
new RBCs.
Koga et al. showed that erythrocyte indices with
glycated hemoglobin in premenopausal women revealed
RBC count to be positively and Hb, MCH, and MCV to
be negatively associated with HbA1c, but none of them
showed any associations with HbA1c in postmenopausal
women (32).
Our findings show that anemia might play a role
in rising HbA1c levels in the presence of T2DM;
consequently, care should be taken before making any
change to the treatment regimen. Our observations also
demonstrate that, in repeated measure ANOVA, HbA1c
levels were significantly higher for anemic patients who
had uncontrolled FBS. As a result, anemia may exaggerate
the picture of glycemic status in this group of patients.
Serum ferritin is a marker of iron status and an acute
phase reactant; it reflects body iron stores in healthy people.
The Third National Health and Nutrition Examination
Survey reported that serum ferritin was associated with
abdominal obesity and insulin resistance (33). One
American study provided evidence that obese patients
with diabetes have significantly higher ferritin levels than
obese patients without diabetes (34).
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